Work Area: Patent law

Latest content

IPR estoppel has teeth in 2022

The Federal Circuit’s recent decisions represent the pendulum swinging to favour patent owners

25 August 2022

Why brand-name pharmaceuticals should look to China’s patent linkage system

Featured in IAM Life Sciences: Key issues for senior life sciences executives 2022

China has recently introduced a unique patent linkage system, which has opened up fresh opportunities for those brand-name pharmaceutical companies that adapt their IP strategies to it.

18 August 2022

Tips and tricks on how to obtain patent protection for polymorphs

Featured in IAM Life Sciences: Key issues for senior life sciences executives 2022

Obtaining patent protection for a polymorph in addition to a primary compound patent may be particularly advantageous, especially if filed successively, as the polymorph patent may add extra time to the patent protection for the modification of an approved drug or a clinical candidate.

18 August 2022

What made Colombia an attractive venue for Ericsson in its patent battle with Apple

The Swedish company has been a prolific filer in a country whose judicial processes strongly favour plaintiffs

11 August 2022

Tillis’s 101 bill will rev the US innovation engine once again

Paul Michel, former Chief Judge of the US Court of Appeals for the Federal Circuit, and ex-USPTO Director David Kappos urge Congress to embrace legislation designed to repair patent eligibility law which they believe the US Supreme Court has distorted

06 August 2022

Experts react to USPTO planned revision of section 101 guidance

While most observers welcome a revisit, many believe that only the Supreme Court or Congress can deliver significant levels of certainty on eligibility

02 August 2022

Developments at the EPO on patenting AI-assisted inventions require close scrutiny

A recent decision handed down by the Boards of Appeal may mean greater patenting opportunities for innovators using AI to help create their inventions

30 July 2022

Teva’s skinny label SCOTUS petition is a must-watch for generics

The move is the company’s final resort as it seeks to overturn a $235 million damages decision that has major IP implications for the entire pharmaceutical industry

28 July 2022

Vidal opens up on PTAB reform, 101 and SEPs in conference dialogue with Iancu

Speaking at an event in Washington DC, the USPTO Director expanded on challenges facing the agency, and how they may be addressed

27 July 2022

We may survive the PTAB but many other small disruptors will not, says Centripetal COO

In an exclusive interview, Jonathan Rogers describes the security company’s experiences of enforcing its patents and explains how he believes Big Tech is colluding to abuse the IPR process

21 July 2022

Unlock unlimited access to all IAM content